150
Participants
Start Date
November 14, 2024
Primary Completion Date
November 30, 2028
Study Completion Date
November 30, 2028
DS-2243a
"Escalation Part: DS-2243a will be administered at escalating doses to determine the RDE~Expansion Part: DS-2243a will be administered at RDE"
RECRUITING
UZ Leuven Europe Leuven, Leuven
RECRUITING
Centre Leon Berard, Lyon
RECRUITING
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL), Amsterdam
RECRUITING
Seoul National University Hospital, Seoul
Lead Sponsor
Daiichi Sankyo
INDUSTRY